before. Unaccountable or stability overages were viewed as unacceptable and would prevent the approval of that product.
Between June 1999 and July 2001, nine sponsors submitted stand-alone NDA applications. The first product was approved in August of 2000. There are currently six approved levothyroxine sodium tablet NDAs, and I have them listed here. We've got Lloyd, Jerome Stevens, Genpharm, Jones, MOVA, and Abbott Pharmaceuticals.
I'd like to conclude by saying that the process that I've just described has had a major impact in improving the quality and consistency of these six FDA-approved products. Important issues, such as overages, content uniformity, and bioavailability, have been addressed, and product-specific dissolution tests ‑‑ I'll repeat that again because it's very important ‑‑ product-specific dissolution tests have been conducted. And it's very important that these were specific to the product because it allows for lot-to-lot consistency and quality evaluation.
These steps go a long way in addressing some